180 Life Sciences Is Looking To Repurpose Biosimilars
CEO Sets Out Strategy Of Pursuing Novel Indications For Off-Patent Biologics
US firm 180 Life Sciences believes that existing anti-TNF biologics have the potential to address a variety of other conditions in which patients currently have unmet needs. CEO Dr Jim Woody tells Generics Bulletin about how the company is exploring new indications for off-patent biologics.
You may also be interested in...
Celltrion has received a pan-European marketing authorization for its Yuflyma high-concentration adalimumab biosimilar, making it the first firm worldwide to register a 100mg/ml rival to the blockbuster Humira brand.
Pfizer has secured FDA approval for its adalimumab biosimilar under the name Abrilada, representing the agency’s 25th biosimilar approval overall. However, patent settlements around the Humira brand mean that Pfizer is not due to enter the market for four years.
Action is needed from both the UK government and the European Commission to prevent a collapse of Northern Ireland’s generics market, according to the BGMA.